Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023278 · ClinicalTrials.gov registry record · Phase 4
The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT05023278 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 100 participants.
The verdict
NCT05023278, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Patients experience pain after their knee replacement surgery - and some may continue to experience persistent pain long after their knee replacement surgery. Traditional pain management strategies reply on pain medication such as opioids for pain control. However, these drugs do not work well for pain associated with movement or the the nerve pain (tingling, electrical sensations) after surgery. In addition, opioids are associated with significant side effects such as nausea, vomiting, respiratory depression, depression, cognitive dysfunction and risk of persistent opioid use. Neuropathic pain medications, such as venlafaxine are effective in managing nerve pain. Recent studies also support its potential role in acute pain management. Here, we propose a prospective randomized clinical trial 1) to evaluate the efficacy of Venlafaxine in reducing pain intensity and opioid consumption at post-operative day 1 (POD1) and 1- week after surgery, and 2) to examine whether the use of Venlafaxine will reduce the incidents of chronic postsurgical pain in TKA patients at 3-month time point.
Interventions
- DRUG Placebo
- DRUG Venlafaxine 37.5 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023278
The ClinicalTrials.gov registry entry for NCT05023278 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05023278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05023278 about?
NCT05023278 is a clinical study titled "The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement". Patients experience pain after their knee replacement surgery - and some may continue to experience persistent pain long after their knee replacement surgery. Traditional pain management strategies reply on pain medication such as opioids for pain control. However, these drugs do not work well for p...
What is the current status of trial NCT05023278?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-05-10. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT05023278?
The interventions under investigation include: Placebo (DRUG), Venlafaxine 37.5 MG (DRUG).
Who is sponsoring clinical trial NCT05023278?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.